Allianz Asset Management Gmb H Fate Therapeutics Inc Transaction History

Allianz Asset Management Gmb H

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$17.78 - $42.39 $547,730 - $1.31 Million	-30,806 Reduced 55.28%	24,918 $617,000
Q1 2022 May 13, 2022	BUY	$29.67 - $60.28 $37,235 - $75,651	1,255 Added 2.3%	55,724 $2.16 Million
Q4 2021 Feb 11, 2022	BUY	$47.84 - $64.34 $1.1 Million - $1.48 Million	22,945 Added 72.79%	54,469 $3.2 Million
Q3 2021 Nov 10, 2021	BUY	$59.27 - $95.73 $65,848 - $106,356	1,111 Added 3.65%	31,524 $1.87 Million
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $957,034 - $1.32 Million	-14,231 Reduced 31.88%	30,413 $2.64 Million
Q1 2021 May 13, 2021	SELL	$72.16 - $117.4 $69,562 - $113,173	-964 Reduced 2.11%	44,644 $3.68 Million
Q4 2020 Feb 16, 2021	BUY	$38.09 - $100.95 $1.74 Million - $4.6 Million	45,608 New	45,608 $4.15 Million
Q2 2020 Aug 14, 2020	SELL	$20.21 - $35.23 $640,050 - $1.12 Million	-31,670 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$17.28 - $31.88 $223,447 - $412,240	-12,931 Reduced 28.99%	31,670 $703,000
Q4 2019 Feb 13, 2020	BUY	$13.39 - $20.73 $8,757 - $13,557	654 Added 1.49%	44,601 $873,000
Q3 2019 Nov 13, 2019	SELL	$15.47 - $22.5 $999,655 - $1.45 Million	-64,619 Reduced 59.52%	43,947 $682,000
Q2 2019 Aug 08, 2019	SELL	$15.61 - $20.44 $15,344 - $20,092	-983 Reduced 0.9%	108,566 $2.2 Million
Q1 2019 May 13, 2019	BUY	$13.15 - $18.71 $15,622 - $22,227	1,188 Added 1.1%	109,549 $1.93 Million
Q4 2018 Feb 14, 2019	BUY	$11.48 - $16.98 $2,628 - $3,888	229 Added 0.21%	108,361 $1.39 Million
Q3 2018 Nov 13, 2018	BUY	$8.75 - $16.29 $946,155 - $1.76 Million	108,132 New	108,132 $1.76 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.